Total-body PET/CT: how will it change theranostics in oncology?

Recent Breakthroughs in PET-CT Multimodality Imaging: Innovations and Clinical Impact

This review presents a detailed examination of the most recent advancements in positron emission tomography-computed tomography (PET-CT) multimodal imaging over the past five years. The fusion of PET and CT technologies has revolutionized medical imaging, offering unprecedented insights into both anatomical structure and functional processes. The analysis delves into key technological innovations, including advancements in image reconstruction, data-driven gating, and time-of-flight capabilities, highlighting their impact on enhancing diagnostic accuracy and clinical outcomes. Illustrative case studies underscore the transformative role of PET-CT in lesion detection, disease characterization, and treatment response evaluation. Additionally, the review explores future prospects and challenges in PET-CT, advocating for the integration and evaluation of emerging technologies to improve patient care. This comprehensive synthesis aims to equip healthcare professionals, researchers, and industry stakeholders with the knowledge and tools necessary to navigate the evolving landscape of PET-CT multimodal imaging.

Expanding Role for Gallium-68 PET Imaging in Oncology

Gallium-68 has gained substantial momentum since 2003 as a versatile radiometal that is extremely useful for application in the development of novel oncology targeting diagnostic radiopharmaceuticals. It is available through both generator produced radioactivity and via cyclotron production methods and can therefore be implemented in either small- or large-scale production facilities. It can also be implemented within different spectrum of infrastructure settings with relative ease. Whilst many of the radiopharmaceuticals are being development and investigated, which is summarized in this manuscript, [68Ga]Ga-SSTR2 and [68Ga]Ga-PSMA has prominence in current clinical guidelines. The novel tracer [68Ga]Ga-FAPi has also gained significant interest in the clinical context. A comparison of the labelling strategies followed to incorporate gallium-68 and fluorine-18 into the same molecular targeting constructs clearly demonstrate that gallium-68 complexation is the most convenient approach. Recently, cold kit based starting products are available to make the small-scale production of gallium-68 radiopharmaceuticals even more efficient when combined with generator produced gallium-68. The regulatory aspects is currently changing to support the implementation of gallium-68 and other diagnostic radiopharmaceuticals, simplifying the translation towards clinical use. Overall, the development of gallium-68 based radiopharmaceuticals is not only rapidly changing the landscape of diagnosis in oncology, but this growth also promotes innovation and progress in new applications of therapeutic radiometals such as lutetium-177 and actinium-225.

PET Molecular Imaging: Old Habits Do Not Die, They Only Evolve into New Applications

The first studies on human applications of radioisotopes for the in vivo targeting of pathophysiological processes began in the late 1930s in Western Europe and the USA with 99mTc [...].